- Home
- MBC vs MYGN Comparison
MBC vs MYGN Comparison
Compare MBC & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MBC
- MYGN
- Stock Information
- Founded
- MBC 1954
- MYGN 1991
- Country
- MBC United States
- MYGN United States
- Employees
- MBC N/A
- MYGN N/A
- Industry
- MBC Agricultural Chemicals
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- MBC Industrials
- MYGN Health Care
- Exchange
- MBC Nasdaq
- MYGN Nasdaq
- Market Cap
- MBC 2.3B
- MYGN 2.0B
- IPO Year
- MBC N/A
- MYGN 1995
- Fundamental
- Price
- MBC $16.05
- MYGN $13.85
- Analyst Decision
- MBC Strong Buy
- MYGN Hold
- Analyst Count
- MBC 1
- MYGN 12
- Target Price
- MBC $23.00
- MYGN $23.92
- AVG Volume (30 Days)
- MBC 675.4K
- MYGN 904.0K
- Earning Date
- MBC 11-05-2024
- MYGN 11-07-2024
- Dividend Yield
- MBC N/A
- MYGN N/A
- EPS Growth
- MBC N/A
- MYGN N/A
- EPS
- MBC 1.14
- MYGN N/A
- Revenue
- MBC $2,709,800,000.00
- MYGN $823,600,000.00
- Revenue This Year
- MBC $2.41
- MYGN $13.82
- Revenue Next Year
- MBC $7.56
- MYGN $4.59
- P/E Ratio
- MBC $14.25
- MYGN N/A
- Revenue Growth
- MBC N/A
- MYGN 12.15
- 52 Week Low
- MBC $13.37
- MYGN $13.81
- 52 Week High
- MBC $20.67
- MYGN $29.30
- Technical
- Relative Strength Index (RSI)
- MBC 35.67
- MYGN 26.49
- Support Level
- MBC $15.63
- MYGN $13.92
- Resistance Level
- MBC $17.02
- MYGN $15.44
- Average True Range (ATR)
- MBC 0.40
- MYGN 0.79
- MACD
- MBC -0.06
- MYGN 0.03
- Stochastic Oscillator
- MBC 19.23
- MYGN 3.06
About MBC MasterBrand Inc.
MasterBrand Inc operates as a residential cabinet manufacturer in North America. It offers a comprehensive portfolio of residential cabinetry products for the kitchen, bathroom, and other parts of the home. The firm sells its products throughout the United States and Canada through three primary channels: dealers, retailers, and builders.
About MYGN Myriad Genetics Inc.
Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.